<?xml version='1.0' encoding='utf-8'?>
<document id="23362713"><sentence text="Inhibitory effect of isoniazid and orlistat combination on mycobacterial ES-31 serine protease in vitro and on the growth of M.tb bacilli in axenic culture."><entity charOffset="21-30" id="DDI-PubMed.23362713.s1.e0" text="isoniazid" /></sentence><sentence text="Isoniazid and orlistat were reported to have inhibitory effect on mycobacterial ES-31 serine protease in vitro and bacterial cell growth in axenic culture"><entity charOffset="0-9" id="DDI-PubMed.23362713.s2.e0" text="Isoniazid" /></sentence><sentence text="" /><sentence text="To study the cumulative effect and understand drug - drug interaction, if any, when isoniazid and orlistat used in combination"><entity charOffset="84-93" id="DDI-PubMed.23362713.s4.e0" text="isoniazid" /></sentence><sentence text="" /><sentence text="Inhibition of mycobacterial ES-31 serine protease by different combinations of orlistat and isoniazid together and individually were studied using azocasein assay"><entity charOffset="92-101" id="DDI-PubMed.23362713.s6.e0" text="isoniazid" /><entity charOffset="147-156" id="DDI-PubMed.23362713.s6.e1" text="azocasein" /><pair ddi="false" e1="DDI-PubMed.23362713.s6.e0" e2="DDI-PubMed.23362713.s6.e0" /><pair ddi="false" e1="DDI-PubMed.23362713.s6.e0" e2="DDI-PubMed.23362713.s6.e1" /></sentence><sentence text=" Inhibition of secretion of excretory secretory ES-31 antigen in Sautan culture medium was studied under axenic condition and growth of M" /><sentence text=" tuberculosis H37Ra bacilli by CFU count on LJ-medium" /><sentence text="" /><sentence text="Orlistat and isoniazid both showed inhibitory activity of ES-31 serine protease in in vitro as well as in vivo"><entity charOffset="0-8" id="DDI-PubMed.23362713.s10.e0" text="Orlistat" /><entity charOffset="13-22" id="DDI-PubMed.23362713.s10.e1" text="isoniazid" /><entity charOffset="58-70" id="DDI-PubMed.23362713.s10.e2" text="ES-31 serine" /><pair ddi="false" e1="DDI-PubMed.23362713.s10.e0" e2="DDI-PubMed.23362713.s10.e0" /><pair ddi="false" e1="DDI-PubMed.23362713.s10.e0" e2="DDI-PubMed.23362713.s10.e1" /><pair ddi="false" e1="DDI-PubMed.23362713.s10.e0" e2="DDI-PubMed.23362713.s10.e2" /><pair ddi="false" e1="DDI-PubMed.23362713.s10.e1" e2="DDI-PubMed.23362713.s10.e1" /><pair ddi="false" e1="DDI-PubMed.23362713.s10.e1" e2="DDI-PubMed.23362713.s10.e2" /></sentence><sentence text=" Individually, isoniazid showed 90% inhibition at 200 ng/ml while orlistat at 250 ng/ml showed 65% inhibition of mycobacterial ES-31 serine protease in vitro"><entity charOffset="15-24" id="DDI-PubMed.23362713.s11.e0" text="isoniazid" /></sentence><sentence text=" A combination of orlistat (250 ng/ml) and isoniazid (200 ng/ml) showed 86% inhibition in vitro while 73% inhibition was observed by orlistat (25 ng/ml) and isoniazid (200 ng/ml) on bacterial growth in axenic culture"><entity charOffset="43-52" id="DDI-PubMed.23362713.s12.e0" text="isoniazid" /><entity charOffset="157-166" id="DDI-PubMed.23362713.s12.e1" text="isoniazid" /><pair ddi="false" e1="DDI-PubMed.23362713.s12.e0" e2="DDI-PubMed.23362713.s12.e0" /><pair ddi="false" e1="DDI-PubMed.23362713.s12.e0" e2="DDI-PubMed.23362713.s12.e1" /></sentence><sentence text="" /><sentence text="Significant inhibition by orlistat suggests that it could be tried in patients with intolerance to isoniazid or in those already developed isoniazid resistance"><entity charOffset="99-108" id="DDI-PubMed.23362713.s14.e0" text="isoniazid" /><entity charOffset="139-148" id="DDI-PubMed.23362713.s14.e1" text="isoniazid" /><pair ddi="false" e1="DDI-PubMed.23362713.s14.e0" e2="DDI-PubMed.23362713.s14.e0" /><pair ddi="false" e1="DDI-PubMed.23362713.s14.e0" e2="DDI-PubMed.23362713.s14.e1" /></sentence><sentence text=" It may also be explored in the suspected TB patients as initial medication in place of antibiotics for clinical relief" /><sentence text="" /></document>